On the Path to Treating Myelofibrosis

Myelofibrosis (MF) is a rare condition that occurs in the bone marrow, disrupting the body’s normal production of red and white blood cells. This type of cancer, which causes scarring in the bone marrow, can develop on its own or from another bone marrow disorder. Patients diagnosed with MF are prone to frequent infections, can develop anemia, tend to bleed and bruise easily, and often suffer from discomfort due to an enlarged spleen.  

Historically, the anti-cancer drug Jakafi (Ruxolitinib) has been used to try to treat Myelofibrosis. However, it has limited effects and only about a third of patients with MF have seen improvement. Xpovio (Selinexor), another anti-cancer therapy, has shown positive outcomes in a number of blood cancers such as lymphoma and myeloma and is now FDA approved to treat those diseases. The Innovative Clinical Research Institute (ICRI) at The Oncology Institute is conducting a clinical trial that evaluates the safety and efficacy two anti-cancer drugs known as Jakafi (Ruxolitinib) and Xpovio (Selinexor) when combined.  

“This trial could lead to more effective and safe treatments for this disease which cannot be cured aside from a bone marrow transplant,” said Dr. Amitabha Mazumder, TOI physician and Principal Investigator for the study. “Bone marrow transplants are high risk procedures and can only be performed in a few patients.”  

Patients with MF who have not had treatment before for their disease are eligible for this trial.  Those interested in participating in the trial should have adequate blood counts, kidney and liver function, as well as a large spleen as the effects of the therapies on these systems will be measured and monitored throughout the study. Jakafi will be given twice daily and Selinexor, given weekly. 

The expected completion date for the study is November 2023. This trial is being conducted by the research of The Oncology Institute, ICRI at the following locations: Glendale, Long Beach, Pasadena, Santa Ana and Whittier.  

Want more information on clinical trials?

Discover a clinical trial that might be right for you

The Oncology Institute Opens Two New Clinics Nationwide

As part of our mission to expand world-class cancer care into local communities, The Oncology Institute of Hope and Innovation (TOI) opened two new state-of-the-art clinics this week — one in California’s High Desert and another in the Tampa Bay area of Florida.

The new location in Victorville, CA is open Monday through Friday from 8:30 AM to 5 PM. Doctors Susmita Sakruti and Vinita Singh are now accepting new patients. 

The clinic in Downtown St. Petersburg, located at 501 Dr. M.L.K. Jr St. South, is also open Monday through Friday from 8:30 AM to 5 PM. Dr. Ali Naboush is ready to serve patients in the community.

TOI is a multi-state cancer care practice dedicated to healing and empowering patients through compassion, innovation, and state-of-the-art medical care. TOI is the largest value-based oncology practice in the U.S., taking accountability for both the quality outcomes as well as the medical costs associated with a population of more than 1 million patients.

With an ongoing focus on quality patient care, the new locations will feature cutting-edge services in addition to top-notch care that is already offered at existing locations throughout Southern California and across the country

Read the official press release announcement for our Victorville clinic here.

Read the official press release announcement for our Downtown St. Petersburg clinic here.

World-class cancer care close to home

Request an appointment at a clinic near you

TOI Named Community Clinic of the Year

We are honored to announce that TOI has been recognized by the Los Angeles Business Journal as Community Clinic of the Year!

The Los Angeles Business Journal’s 2021 Health Care Leadership Panel & Awards honors the accomplishments of individuals and organizations that have made great strides in providing leading-edge healthcare.

As one of the nation’s leading community-based oncology providers, TOI is proud to be an integral part of the fabric of the communities we serve — committed to providing accessible care for all. By centering care on the patient, focusing on outcomes, and constantly innovating, TOI is changing oncology care for the better.

Thank you to our incredible team of doctors, nurses, advanced practice providers, and clinic staff who put our patients first every day!

With you through every phase of your cancer journey

Learn more about starting treatment at a location near you

Clinical Trials at ICRI: August Round-Up

Deciding to participate in a clinical trial is a personal decision that can potentially have a profound beneficial impact on a patient’s cancer journey. Although many patients may be interested in participating in a cutting-edge clinical trial, questions around where to begin, eligibility or even making sense of scientific descriptions can pose a challenge. 

TOI’s Innovative Clinical Research Institute (ICRI) team has made clinical trial participation more accessible than ever. Below are just a few of the many progressive clinical studies being conducted at ICRI: 

HiberCell, PGG-MEL2021 

  • Cancer Type Targeted: Melanoma
  • Who’s Eligible: Patients with Stage III, Resectable Melanoma 
  • Description/Objective: To determine the pathological response rate in the surgically removed specimen after completion of therapy given with Imprime PGG plus pembrolizumab vs pembrolizumab monotherapy. 
  • Clinical Trial Phase: II*  
  • *If a new treatment is found to be safe in phase I clinical trials, a phase II clinical trial is done to see if it works in certain types of cancer for a specified duration.¹ Benefits during this phase can include improvement in quality of life. 
  • Minimum Age Requirement: 18 years or older 
  • Estimated Study Duration: 2 years (Through 2023) 
  • Location(s): Downey, Glendale, Long Beach, Whittier 

AnHeart Therapeutics Inc. AB-106-G208 

  • Cancer Type Targeted: Lung Cancer (Non-small cell lung cancer) or other solid tumors 
  • Who’s Eligible: Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors 
  • Description/Objective: To evaluate safety and efficacy of the anti-cancer drug, Taletrectinib, in subjects with NSCLC. Patients will continue with treatment and tumor response will be evaluated on a regular basis until progression of disease is determined by the investigator. Long-term survival follow up will be conducted as well. 
  • Clinical Trial Phase: II 
  • Minimum Age Requirement: 18 years or older 
  • Estimated Study Duration: Up to 4 years 
  • Location(s): Glendale, Long Beach, Whittier, Santa Ana 

Incyte Corporation, INCMOR0208-301 

  • Cancer Type Targeted: Lymphoma 
  • Who’s Eligible: Patients with Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma 
  • Description/Objective: This Phase 3 double-blind, placebo-controlled, randomized study is designed to investigate whether anti-cancer drugs, Tafasitamab and Lenalidomide – as an add-on to Rituximab, provides improved clinical benefit; as compared to Lenalidomide as an add-on to Rituximab in patients with the targeted cancers. 
  • Clinical Trial Phase: III* 
    • Treatments that have been shown to work in phase II clinical trials must succeed in one more phase before they’re approved for general use. Phase III clinical trials compare the safety and effectiveness of the new treatment against the current standard treatment.² 
  • Minimum Age Requirement: 18 years or older 
  • Estimated Study Duration: Up to 6 years 
  • Location(s): Glendale, Long Beach, Whittier, Santa Ana, and Pasadena 

It’s best to speak to a primary care provider or oncologist before making the decision to participate in a clinical trial. By participating in a clinical trial, patients are not only able to help researchers learn more about treatment, but can improve the quality of life and care for future patients. 

For a complete list of clinical trials at ICRI, click here.

References:  

1 & 2: Types of Phases and Clinical Trials – American Cancer Society 

Want more information on clinical trials?

Discover a clinical trial that might be right for you

5 Fast Facts: Sarcoma

Known as the forgotten cancer, sarcomas are rare, but hard to spot and potentially very dangerous. The term “sarcoma” is derived from a Greek word meaning “fleshy growth.” There are two primary categories of sarcomas: bone and soft tissue¹.

Are you familiar with sarcomas and how they are diagnosed? Learn more with our Five Fast Facts about sarcoma.

  1. Sarcomas can appear anywhere in the body. This is due to the fact that sarcomas arise from a variety of tissue structures (collectively referred to as the body’s “connective tissues”) including, but not limited to²:
    • Nerves 
    • Muscles 
    • Joints
    • Bone
    • Fat
    • Blood Vessels

2. Sarcomas are often difficult to detect because they can hide out deep within the body. As they grow, however, symptoms can start to appear. These symptoms may include³: 

    • Pain in the affected area, which may be worse in the evening
    • Swelling, which may start weeks after pain begins
    • A new lump or a lump that’s growing (anywhere in the body)
    • Blood in the stool or vomiting

3. Survival rates for sarcomas vary and there are many factors that must be considered: 

    • Type of sarcoma
    • Stage of a patient’s sarcoma 
    • Patient’s age at time of diagnosis 
    • Types of treatment a patient receives 

4. Though there are no known causes of sarcoma, the risk factors associated with the disease include4: 

    • Genetic disorders 
    • Chemical exposure
    • Radiation exposure
    • Long-term swelling   

Approximately 15,000 new cases of sarcoma are diagnosed in the U.S. every year. Sarcomas are one of the top 5 most commonly diagnosed cancers among children. However, sarcomas can occur in anyone regardless of age.

References 

  1. https://www.reininsarcoma.org/what-is-sarcoma-2/ 
  2. https://www.curesarcoma.org/patient-resources/ 
  3. https://www.cancer.org/cancer/soft-tissue-sarcoma/detection-diagnosis-staging/signs-symptoms.html 
  4. https://sarcomaalliance.org/detection-and-treatment/ 

With you through every phase of your cancer journey

Learn more about starting treatment at a location near you

The Oncology Institute Expands to San Diego County

The Oncology Institute (TOI) is now proudly serving patients in the Greater San Diego area. Two new locations in Chula Vista and Vista opened on Monday, August 2nd. A third location in Hillcrest is set to open in the fall.

Doctors Jeffrey Andrey, MD, and Anwer Shaikh, MD, will be seeing patients at both the Chula Vista and Vista locations, while Dr. Babak Baseri will be treating patients at the Vista clinic. Both locations are open Monday through Friday, from 8:30 AM to 5:00 PM.

TOI’s value-based care model brings comprehensive, integrated cancer care into community settings, including Clinical Trials, Palliative Care programs, Stem Cell Transplants, Transfusions, and more. TOI is committed to healing and empowering cancer patients through compassion, innovation and state-of-the-art medical care.

Read the official press release here.

World-class cancer care close to home

Request an appointment at a clinic near you